A new ADHD drug just got FDA approval. Here's what makes it different.
Headline from ABC 17 Mid-Missouri
The Food and Drug Administration (FDA) just approved Simtriyo (centanafadine), a new norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant. The medication treats ADHD in adults, teens, and children ages 6 and up weighing at least 44 pounds.
ABC 17 Mid-Missouri's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The Food and Drug Administration (FDA) just approved Simtriyo (centanafadine), a new norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant. The medication treats ADHD in adults, teens, and children ages 6 and up weighing at least 44 pounds.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
A new ADHD drug just got FDA approval. Here's what makes it different. | Since Then
